New Delhi, November 29 (IANS). Professor Dr. Khalid Raza, one of the world’s top scientists, has done excellent research on Artificial Intelligence (AI) guided drug system for breast cancer. Dr. Raza is Associate Professor in the Department of Computer Science at Jamia Millia Islamia. Their tools will focus on identifying therapeutic targets and new treatment strategies for breast cancer.
Dr. Seeing Raza’s success, the Indian Council of Medical Research has awarded him a prestigious research grant of Rs 94 lakh. Dr. Raza has been selected by Stanford University as one of the top two percent scientists in the world for three consecutive years. This highly competitive grant will help Dr. Raza and his team develop cutting-edge tools for Artificial Intelligence guided drug design.
More research will now be done on one such promising drug compound already patented by Dr. Raza. This research addresses important challenges in the treatment of breast cancer. This is expected to yield transformative results that could impact healthcare practices globally.
Vice Chancellor of Jamia Millia Islamia Prof. Mazhar Asif says that this is a very proud moment for Jamia Millia Islamia. The grant awarded to Dr. Raza by the Indian Council of Medical Research underlines the University’s commitment to fostering research excellence and innovation.
Dr. Raza said that I feel very honored to receive this grant from the Indian Council of Medical Research. This is a great opportunity to contribute to better health outcomes for millions of people. This three-year funding will facilitate advanced experiments. This will accelerate the development of innovative solutions for the treatment of breast cancer.
According to Jamia University, Dr. Khalid Raza is a distinguished researcher in the application of artificial intelligence in healthcare. He focuses on designing and optimizing drug compounds through Artificial Intelligence based multi target docking, therapeutics. His work has greatly advanced the treatment of complex diseases, including cancer.
–IANS
GCB/ABM
